TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascelia Pharma AB ( (SE:ACE) ) has issued an update.
Ascelia Pharma AB is nearing the submission of its New Drug Application (NDA) for Orviglance to the FDA, expected by early September 2025. The completion of the clinical development phase, marked by positive Phase 3 results, reinforces the drug’s market potential. The company has secured additional financing and is in discussions with potential partners for commercialization, aiming to enhance diagnostic options for cancer patients with kidney issues.
More about Ascelia Pharma AB
Ascelia Pharma AB operates in the pharmaceutical industry, focusing on developing novel drugs for orphan oncology indications. Their primary product, Orviglance, is a magnetic resonance imaging (MRI) contrast agent designed to improve liver lesion visualization in patients with impaired kidney function. The company is actively working on regulatory submissions and exploring commercialization partnerships.
Average Trading Volume: 1,014,621
Technical Sentiment Signal: Buy
Current Market Cap: SEK538.9M
For detailed information about ACE stock, go to TipRanks’ Stock Analysis page.